Committed to harnessing the power and potential of genome editing to develop transformative medicines for patients suffering from serious diseases

Editas Medicine (NASDAQ: EDIT) is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

Year Invested: 2013
Location: Cambridge, Mass.

Recent News

March 16, 2017
Editas Medicine, Inc. Announces Pricing of $90 Million Offering of Common Stock

March 15, 2017
Editas Medicine, Inc., Announces Proposed Offering of Common Stock

March 14, 2017
Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases

Read More News

Associated Team Members

Alexis Borisy